A 60% reduction in the risk of disease progression or death is a striking number in any oncology trial, but the design choice behind it sharpens the result considerably. Genmab’s Phase 3 EPCORE DLBCL-4 trial tested epcoritamab plus lenalidomide against R-GemOx, a platinum-based chemoimmunotherapy regimen, in patients with relapsed or refractory DLBCL who had already failed or were ineligible for both autologous stem cell transplant and CAR-T. That is a population without good options left, and the trial beat its comparator with a hazard ratio of 0.40 (95% CI 0.30, 0.55; p less than 0.0001) under U.S. censoring rules, and 0.44 (95% CI 0.33, 0.60; p less than 0.0001) outside the U.S. Both figures crossed a prespecified threshold, and the safety profile added no new signals beyond what each individual agent already carries.
The clinical architecture here deserves attention. Epcoritamab received accelerated FDA approval in May 2023 for third-line and later DLBCL, based on single-arm data. EPCORE DLBCL-4 operates in second-line and beyond, enrolling patients after at least one prior therapy, and it does so with a randomized, active-controlled design. That move from single-arm accelerated approval to a positive Phase 3 versus a standard-of-care backbone is exactly the kind of dataset regulators want to see for a full or expanded approval, particularly when the combination is chemotherapy-free and fixed-duration. The lenalidomide pairing is not incidental: it positions epcoritamab in a space where oral immunomodulatory combinations have already been tested, building a case for both efficacy and outpatient tolerability.
Genmab and AbbVie are running epcoritamab across several disease settings simultaneously, including a trial in newly diagnosed DLBCL paired with R-CHOP and another in untreated follicular lymphoma with lenalidomide and rituximab. The DLBCL-4 readout validates the lenalidomide combination strategy specifically, which matters for the FL frontline trial’s eventual interpretation. The competitive landscape in R/R DLBCL already includes agents such as polatuzumab vedotin and CAR-T cell therapies, so epcoritamab’s path to broader use depends on demonstrating superiority over chemo-based standards rather than just activity in heavily pretreated patients, which these topline results begin to do.
Full data are headed to a medical meeting not yet named. The number that will define the submission package is overall survival, which topline results have not yet addressed. Whether the PFS advantage translates into a survival signal in this specific population is the single result that will determine how aggressively regulators, and eventually payers, position this chemotherapy-free regimen in second-line DLBCL.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
Roche’s Englumafusp Plus Glofitamab Combination Shows Why Phase 1 Trial Design Is the Real Competitive Moat in Bispecific Oncology
1 month ago[…] CD20xCD3 bispecific that earned FDA accelerated approval in June 2023 for relapsed or refractory DLBCL. Two T-cell engagers. Two distinct B-cell antigens. One protocol, one patient population with […]
Comments are closed.